Everything’s warmer this winter in Delhi, even a dengue discussion. For years Navin Khanna has studied dengue and other infections with a quiet purposefulness. As he settles into the cane chair, at the faculty lounge and boots up his MacBook, the academic aloofness of the place recedes. In the 26 years that Khanna has been at the International Centre for Genetic Engineering and Biotechnology (ICGEB), he has developed 26 diagnostic kits; 23 of which are in the market.

“It wasn’t mathematics,” he says, with a dismissive laugh. “India is the epicentre of dengue but we under report it. I have suffered from dengue, it can be fatal.”

Come July every year, dengue affects even the non-infected. A constant fear of the disease at the slightest warming of the body lurks in most households. Not the infection but more so, its detection. Most pathology labs still take anywhere between 48-72 hours to report results, which is a long duration for the disease to either turn fatal or fleece the patient in hurried hospitalisations. The fact that there’s now a Day-1 test which can detect infection and its extent on the very day a person gets a fever is just about reaching patients. Still early days, though.

At ICGEB, Khanna developed this three-in-one test which is the only diagnostics of its kind in the world. And it started with a missive from the late President APJ Abdul Kalam, also a former chief of the Defence Research Development Organisation (DRDO).

‘One more try’

Sometime in 2006, DRDO came knocking on Khanna’s door to check if he worked on dengue. The defense centre in Jhansi was unable to battle the disease and Khanna by then had developed a dozen or so diagnostic kits for various infections. Since he had no readymade technology for dengue, he refused. Then, he received a letter from Kalam. It was basically an S.O.S. Dengue was a national priority; refusal wasn’t an option.

But as soon as Khanna developed the test, he had a dilemma at hand. Anything done for DRDO was a closed affair whereas being at ICGEB meant sharing every tech with 60+ member countries, including Pakistan and Bangladesh. Khanna and team had to give it another try—a completely new technology avoiding infringement on his own patent on the previous test. “We realised just doing a dengue antigen or dengue antibody test won’t be enough. So we developed a three-marker test,” says Khanna, group leader at the Recombinant Gene Products Laboratory.

That’s important in a country like India where you can get dengue several times because there are four types of dengue virus—leading to four serotypes. (Serotypes are a class within an organism based on the antigens they produce.) A person generally recovers from primary dengue unless the virus load is very high.


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.